TISIDB

Summary
Symbol	INHBA
Name	inhibin, beta A
Aliases	inhibin, beta A (activin A, activin AB alpha polypeptide); FSH-releasing protein; Inhibin, beta-1; activin b ......
Chromosomal Location	7p15-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted.
Domain	PF00019 Transforming growth factor beta like domain PF00688 TGF-beta propeptide
Function	Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. Inhibins appear to oppose the functions of activins.

> Gene Ontology [ TOP ]
Biological Process	GO:0000082 G1/S transition of mitotic cell cycle GO:0001541 ovarian follicle development GO:0001553 luteinization GO:0001558 regulation of cell growth GO:0001654 eye development GO:0001704 formation of primary germ layer GO:0001706 endoderm formation GO:0001707 mesoderm formation GO:0001818 negative regulation of cytokine production GO:0001942 hair follicle development GO:0002244 hematopoietic progenitor cell differentiation GO:0002262 myeloid cell homeostasis GO:0002521 leukocyte differentiation GO:0002573 myeloid leukocyte differentiation GO:0002683 negative regulation of immune system process GO:0002694 regulation of leukocyte activation GO:0002695 negative regulation of leukocyte activation GO:0002761 regulation of myeloid leukocyte differentiation GO:0002762 negative regulation of myeloid leukocyte differentiation GO:0006869 lipid transport GO:0007050 cell cycle arrest GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway GO:0007292 female gamete generation GO:0007369 gastrulation GO:0007423 sensory organ development GO:0007492 endoderm development GO:0007498 mesoderm development GO:0007548 sex differentiation GO:0008406 gonad development GO:0008544 epidermis development GO:0008584 male gonad development GO:0008585 female gonad development GO:0009914 hormone transport GO:0010817 regulation of hormone levels GO:0010862 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010876 lipid localization GO:0016049 cell growth GO:0020027 hemoglobin metabolic process GO:0021537 telencephalon development GO:0021544 subpallium development GO:0021756 striatum development GO:0021773 striatal medium spiny neuron differentiation GO:0021872 forebrain generation of neurons GO:0021879 forebrain neuron differentiation GO:0021953 central nervous system neuron differentiation GO:0022404 molting cycle process GO:0022405 hair cycle process GO:0022412 cellular process involved in reproduction in multicellular organism GO:0022602 ovulation cycle process GO:0023061 signal release GO:0030098 lymphocyte differentiation GO:0030099 myeloid cell differentiation GO:0030183 B cell differentiation GO:0030218 erythrocyte differentiation GO:0030225 macrophage differentiation GO:0030308 negative regulation of cell growth GO:0030728 ovulation GO:0030900 forebrain development GO:0032274 gonadotropin secretion GO:0032276 regulation of gonadotropin secretion GO:0032277 negative regulation of gonadotropin secretion GO:0032278 positive regulation of gonadotropin secretion GO:0032354 response to follicle-stimulating hormone GO:0032609 interferon-gamma production GO:0032649 regulation of interferon-gamma production GO:0032689 negative regulation of interferon-gamma production GO:0032844 regulation of homeostatic process GO:0032846 positive regulation of homeostatic process GO:0032924 activin receptor signaling pathway GO:0034101 erythrocyte homeostasis GO:0034698 response to gonadotropin GO:0035929 steroid hormone secretion GO:0035987 endodermal cell differentiation GO:0036314 response to sterol GO:0036315 cellular response to sterol GO:0038034 signal transduction in absence of ligand GO:0042035 regulation of cytokine biosynthetic process GO:0042036 negative regulation of cytokine biosynthetic process GO:0042089 cytokine biosynthetic process GO:0042095 interferon-gamma biosynthetic process GO:0042107 cytokine metabolic process GO:0042113 B cell activation GO:0042303 molting cycle GO:0042326 negative regulation of phosphorylation GO:0042476 odontogenesis GO:0042493 response to drug GO:0042541 hemoglobin biosynthetic process GO:0042633 hair cycle GO:0042698 ovulation cycle GO:0042701 progesterone secretion GO:0043010 camera-type eye development GO:0043588 skin development GO:0043900 regulation of multi-organism process GO:0043902 positive regulation of multi-organism process GO:0044057 regulation of system process GO:0044060 regulation of endocrine process GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044843 cell cycle G1/S phase transition GO:0045072 regulation of interferon-gamma biosynthetic process GO:0045077 negative regulation of interferon-gamma biosynthetic process GO:0045137 development of primary sexual characteristics GO:0045577 regulation of B cell differentiation GO:0045578 negative regulation of B cell differentiation GO:0045619 regulation of lymphocyte differentiation GO:0045620 negative regulation of lymphocyte differentiation GO:0045637 regulation of myeloid cell differentiation GO:0045638 negative regulation of myeloid cell differentiation GO:0045639 positive regulation of myeloid cell differentiation GO:0045646 regulation of erythrocyte differentiation GO:0045648 positive regulation of erythrocyte differentiation GO:0045649 regulation of macrophage differentiation GO:0045650 negative regulation of macrophage differentiation GO:0045786 negative regulation of cell cycle GO:0045926 negative regulation of growth GO:0046545 development of primary female sexual characteristics GO:0046546 development of primary male sexual characteristics GO:0046660 female sex differentiation GO:0046661 male sex differentiation GO:0046879 hormone secretion GO:0046880 regulation of follicle-stimulating hormone secretion GO:0046881 positive regulation of follicle-stimulating hormone secretion GO:0046882 negative regulation of follicle-stimulating hormone secretion GO:0046883 regulation of hormone secretion GO:0046884 follicle-stimulating hormone secretion GO:0046887 positive regulation of hormone secretion GO:0046888 negative regulation of hormone secretion GO:0048332 mesoderm morphogenesis GO:0048333 mesodermal cell differentiation GO:0048511 rhythmic process GO:0048608 reproductive structure development GO:0048872 homeostasis of number of cells GO:0050864 regulation of B cell activation GO:0050865 regulation of cell activation GO:0050866 negative regulation of cell activation GO:0050869 negative regulation of B cell activation GO:0050886 endocrine process GO:0051047 positive regulation of secretion GO:0051048 negative regulation of secretion GO:0051051 negative regulation of transport GO:0051249 regulation of lymphocyte activation GO:0051250 negative regulation of lymphocyte activation GO:0060021 palate development GO:0060278 regulation of ovulation GO:0060279 positive regulation of ovulation GO:0060389 pathway-restricted SMAD protein phosphorylation GO:0060393 regulation of pathway-restricted SMAD protein phosphorylation GO:0060395 SMAD protein signal transduction GO:0060986 endocrine hormone secretion GO:0061029 eyelid development in camera-type eye GO:0061458 reproductive system development GO:0070723 response to cholesterol GO:0071371 cellular response to gonadotropin stimulus GO:0071372 cellular response to follicle-stimulating hormone stimulus GO:0071396 cellular response to lipid GO:0071397 cellular response to cholesterol GO:0071407 cellular response to organic cyclic compound GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway GO:0090100 positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway GO:0097154 GABAergic neuron differentiation GO:0097191 extrinsic apoptotic signaling pathway GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand GO:0097305 response to alcohol GO:0097306 cellular response to alcohol GO:0098773 skin epidermis development GO:1902105 regulation of leukocyte differentiation GO:1902106 negative regulation of leukocyte differentiation GO:1903531 negative regulation of secretion by cell GO:1903532 positive regulation of secretion by cell GO:1903706 regulation of hemopoiesis GO:1903707 negative regulation of hemopoiesis GO:1903708 positive regulation of hemopoiesis GO:2000241 regulation of reproductive process GO:2000243 positive regulation of reproductive process GO:2001233 regulation of apoptotic signaling pathway GO:2001235 positive regulation of apoptotic signaling pathway GO:2001236 regulation of extrinsic apoptotic signaling pathway GO:2001238 positive regulation of extrinsic apoptotic signaling pathway GO:2001239 regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001241 positive regulation of extrinsic apoptotic signaling pathway in absence of ligand
Molecular Function	GO:0005125 cytokine activity GO:0005126 cytokine receptor binding GO:0005160 transforming growth factor beta receptor binding GO:0005179 hormone activity GO:0008083 growth factor activity GO:0017046 peptide hormone binding GO:0033218 amide binding GO:0033612 receptor serine/threonine kinase binding GO:0034711 inhibin binding GO:0042277 peptide binding GO:0042562 hormone binding GO:0046982 protein heterodimerization activity GO:0070696 transmembrane receptor protein serine/threonine kinase binding GO:0070697 activin receptor binding GO:0070699 type II activin receptor binding
Cellular Component	GO:0043509 activin A complex GO:0043511 inhibin complex GO:0043512 inhibin A complex GO:0048180 activin complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04060 Cytokine-cytokine receptor interaction hsa04350 TGF-beta signaling pathway hsa04550 Signaling pathways regulating pluripotency of stem cells
Reactome	R-HSA-2473224: Antagonism of Activin by Follistatin R-HSA-209822: Glycoprotein hormones R-HSA-392499: Metabolism of proteins R-HSA-209952: Peptide hormone biosynthesis R-HSA-2980736: Peptide hormone metabolism R-HSA-162582: Signal Transduction R-HSA-1502540: Signaling by Activin

Summary
Symbol	INHBA
Name	inhibin, beta A
Aliases	inhibin, beta A (activin A, activin AB alpha polypeptide); FSH-releasing protein; Inhibin, beta-1; activin b ......
Chromosomal Location	7p15-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between INHBA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	INHBA
Name	inhibin, beta A
Aliases	inhibin, beta A (activin A, activin AB alpha polypeptide); FSH-releasing protein; Inhibin, beta-1; activin b ......
Chromosomal Location	7p15-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of INHBA in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	INHBA
Name	inhibin, beta A
Aliases	inhibin, beta A (activin A, activin AB alpha polypeptide); FSH-releasing protein; Inhibin, beta-1; activin b ......
Chromosomal Location	7p15-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of INHBA in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-2.018	0.0121
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-2.481	0.102
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-1.68	0.184
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-1.126	0.0715
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.861	0.635
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-1.445	0.582
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.327	0.625
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.634	0.547
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.136	0.898
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.669	0.574
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	2.414	0.095
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.386	0.119

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of INHBA in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	1.4	9.7	0.0589
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	1.7	9.4	0.0895
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	11.8	-7	0.577
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	18.2	-10.5	0.576
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	3.7	-1.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	7.1	-0.9	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	7.7	-7.7	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	8.3	-8.3	1

Summary
Symbol	INHBA
Name	inhibin, beta A
Aliases	inhibin, beta A (activin A, activin AB alpha polypeptide); FSH-releasing protein; Inhibin, beta-1; activin b ......
Chromosomal Location	7p15-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of INHBA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	INHBA
Name	inhibin, beta A
Aliases	inhibin, beta A (activin A, activin AB alpha polypeptide); FSH-releasing protein; Inhibin, beta-1; activin b ......
Chromosomal Location	7p15-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of INHBA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by INHBA. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	INHBA
Name	inhibin, beta A
Aliases	inhibin, beta A (activin A, activin AB alpha polypeptide); FSH-releasing protein; Inhibin, beta-1; activin b ......
Chromosomal Location	7p15-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of INHBA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	INHBA
Name	inhibin, beta A
Aliases	inhibin, beta A (activin A, activin AB alpha polypeptide); FSH-releasing protein; Inhibin, beta-1; activin b ......
Chromosomal Location	7p15-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of INHBA expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	INHBA
Name	inhibin, beta A
Aliases	inhibin, beta A (activin A, activin AB alpha polypeptide); FSH-releasing protein; Inhibin, beta-1; activin b ......
Chromosomal Location	7p15-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between INHBA and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	INHBA
Name	inhibin, beta A
Aliases	inhibin, beta A (activin A, activin AB alpha polypeptide); FSH-releasing protein; Inhibin, beta-1; activin b ......
Chromosomal Location	7p15-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting INHBA collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse INHBA